314,800 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by Norges Bank

Norges Bank bought a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 314,800 shares of the company’s stock, valued at approximately $3,472,000. Norges Bank owned 0.59% of Stoke Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its holdings in Stoke Therapeutics by 9.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company’s stock valued at $3,885,000 after buying an additional 26,870 shares in the last quarter. State Street Corp increased its holdings in Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after purchasing an additional 137,145 shares during the period. Jane Street Group LLC raised its position in Stoke Therapeutics by 338.2% during the 3rd quarter. Jane Street Group LLC now owns 330,442 shares of the company’s stock valued at $4,061,000 after purchasing an additional 255,028 shares in the last quarter. Barclays PLC lifted its holdings in shares of Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after buying an additional 47,239 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Stoke Therapeutics by 9.7% in the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after acquiring an additional 76,661 shares during the period.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $6.52 on Friday. The business has a fifty day moving average price of $8.39 and a 200-day moving average price of $10.56. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $17.58. The stock has a market capitalization of $352.59 million, a price-to-earnings ratio of -3.10 and a beta of 1.09.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now directly owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,532 shares of company stock worth $143,332. Company insiders own 11.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Chardan Capital reissued a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $24.67.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.